ART-Plan+ (v.3.0.0)

K242822

Therapanacea SAS · cleared 2025-02-25 · product code MUJ · Radiology

Premarket evidence — what FDA accepted

Device typesamd
source quote (p.6)
ART-Plan+ is a software platform allowing contour regions of interest on 3D images and to provide an automatic treatment plan.
Algorithmdeep-learning based automatic segmentation; AI delineation method
source quote (p.6)
ART-Plan+ offers deep-learning based automatic segmentation of OARs and LNs for the following localizations: -Head and neck (on CT images) -Thorax/breast (on CT images) -Abdomen (on CT and male on MR images) -Pelvis male (on CT and MR images) -Pelvis female (on CT images) -Brain (on CT images and MR images) ART-Plan+ offers deep-learning based automatic segmentation of targets for the following localizations: Deep learning algorithm. The proposed device and primary predicate share an AI delineation method.
Adaptive (vs locked)FDA source did not state this
PCCPFDA source did not state this
Cybersecurity addressedFDA source did not state this

Validation studies (7)

Retrospective clinical

n=24 patients

endpoints: DSC

Retrospective clinical

n=18 patients

endpoints: clinical acceptability (A, B, C scale)

Retrospective clinical

n=24 patients

endpoints: Mean DSC

Reader study (MRMC)

n=13 patients

endpoints: Mean DSC (annotate) vs Mean DSC (inter-expert)

Retrospective clinical

n=51 patients

endpoints: lesion-wise sensitivity; lesion-wise precision; lesion-wise DSC similarity coefficient; patient-wise DSC similarity coefficient; patient-wise false positive

Retrospective clinical

n=43 patients

endpoints: sensitivity; DSC

Retrospective clinical

n=20 patients

endpoints: effectiveness difference (%) in DVH achieved goals between manual plans and automatic plans; % of clinical acceptable automatic plans after expert review

Reported performance (6 observations)

sensitivityas written: “mean lesion-wise sensitivity0.86
source quote (p.10)
The lesion-wise sensitivity is equal to or superior to state-of-the-art as benchmark: mean lesion-wise sensitivity ≥ 0.86
ppvas written: “mean lesion-wise precision0.7
source quote (p.10)
The lesion-wise precision is equal to or superior to state-of-the-art as benchmark: mean lesion-wise precision ≥ 0.70
diceas written: “mean lesion-wise DSC similarity coefficient (DSC)0.78
source quote (p.10)
The lesion-wise DSC similarity coefficient (DSC) is equal to or superior to state-of-the-art as benchmark: mean lesion-wise DSC ≥ 0.78
diceas written: “mean patient-wise DSC similarity coefficient (DSC)0.83
source quote (p.10)
The patient-wise DSC similarity coefficient (DSC) is equal to or superior to state-of-the-art as benchmark: mean patient-wise DSC ≥ 0.83
sensitivityas written: “mean sensitivity (Glioblastoma)0.8
source quote (p.10)
The sensitivity is equal to or superior to state-of-the-art as benchmark: mean sensitivity ≥ 0.80
diceas written: “mean DSC (Glioblastoma)0.76
source quote (p.10)
The DSC is equal to or superior to state-of-the-art as benchmark: mean DSC ≥ 0.76

Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.

Predicate network

Postmarket — what happened after clearance

35
recalls in product code, 24mo
17
MAUDE reports in code, 12mo
-50%
vs code's own 3-yr baseline
3
drift signals on this device
  • re_clearance

    The FDA AI/ML device list shows a newer 510(k) K253091 (decision 2025-12-23) from Therapanacea Sas for a matching device line ("ART-Plan+ (v3.1.0)") — a new clearance for the same line is a change event.

    first seen 2026-07-08 · k_number:K253091

  • recall_reason_pattern

    Software/algorithm-related recall in product code MUJ (Philips Medical Systems (Cleveland) Inc, initiated 2025-08-05): "Due to a software issue, there is a potential image error of the Region of Interest for expansion/contraction for HFP (Head First Prone), FFS (Feet First Supine) and FFP (Feet Firs" Recalling firm is another firm in the same product code.

    first seen 2026-07-08 · recall res_event_number:97049

  • recall_reason_pattern

    Software/algorithm-related recall in product code MUJ (Philips Medical Systems (Cleveland) Inc, initiated 2025-07-17): "Due to software issue, Radiation Therapy Planning system may provide incorrect dataset calculations when performing the "Stopping Power Ratio" (SPR) ," Recalling firm is another firm in the same product code.

    first seen 2026-07-08 · recall res_event_number:97309

Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device). Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.

Reimbursement — how devices like this got paid

Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).

RIGOR™ Precedent · public FDA/CMS data · descriptive decision-support, not regulatory or reimbursement advice. Share this page: radar.healthai.com/precedent/device/K242822